ABSTRACT
Introduction
Insulin self-administration is an indispensable component of diabetes management and the importance of guiding patients towards best injection practice has increasingly been recognized in accordance with growing awareness of the critical role of the correct injection technique in achieving optimal control of diabetes [1] [2] [3] [4] [5] [6] [7] .
Incorrect selection of injection site or delivery device and inappropriate injection technique are considered to modify insulin absorption parameters, leading to higher amount of insulin use and higher glycated haemoglobin (HbA 1c ) values as well as to glycaemic variability, unexplained hypoglycaemia and poor longterm outcomes [8] [9] [10] . Therefore, correct insulin injection technique and correct choice of injection site and delivery devices have been considered as important as providing optimal (type and dose) insulin therapy in achievement of glycaemic goal in diabetes [5, 11] .
Identification of patient, provider, and healthcare system based barriers of initiating and adhering to insulin injection therapy is a critical step toward successful diabetes self-management [5, [12] [13] [14] [15] [16] . Optimal delivery and effect of all injectable agents rely on correct injection technique [17] , emphasizing the role of enhanced awareness of the good injection practices among healthcare professionals (HCPs) as well as patients [5, 9, 18] . Several guidelines on insulin self-administration are available across the world as well as in India, whereas as consistently reported by several studies across the globe, there is a significant gap between the recommendations of the guidelines and actual insulin injection practice [5, 8, 10, [19] [20] [21] .
Moreover, recent advances in device manufacturing, newer research findings and updated international guidelines necessitate renewed commitment toward optimizing insulin injection practices [5] .
Therefore, this consensus statement aimed to review the current guidelines and available evidence to provide a simple and easily implementable practical educational guideline on insulin injection practice for both HCPs and patients in terms of preparation and selection of injection sites, site rotation, selection of the device, storage of insulins, safety precautions, sharp disposal practice and complications.
Materials and methods
An expert panel consisting of 9 endocrinology specialists from university and state hospitals met to develop consensus on insulin injection practices in insulin-treated patients with diabetes in the Indian setting. The panel critically analysed published data from guidelines, clinical trials and real world evidence and agreed on a series of recommendations supported by scientific evidence and experts' clinical opinion. The proposed consensus planned to provide a simple and easily implementable practical educational guideline for insulin injection practice for both HCPs and patients, in terms of a) the injection sites (preparation of site of injection, choosing the injection site, site rotation), b) choice of device and storage of insulins, and c) safety precautions, sharp disposal practice and complications ( Figure 1 ).
Injection site

Injection site preparation
Current guideline recommendation on injection site preparation indicates the injection site should be clean and dry, and soap and water can therefore be used for unclean sites with no need for disinfection, whereas whenever use of alcohol swabs is needed, the site should be dried before injecting (Table 1) [5, [22] [23] [24] [25] . However, disinfection is required in institutional settings such as hospitals and nursing homes, particularly if the site is found to be unclean. If alcohol is used, it must be allowed to dry completely before the injection is given [26] .
Consensus statement on injection site preparation
The expert panel recommends that the injection must be given to clean site using clean hands and after inspection and palpation, with use of soap and water when it is necessary to clean the site of injection. Disinfection of the site or the device is not recommended, while if alcohol swabs are used, then the area must be allowed to dry before the injection.
Consensus statement 1. Injection site preparation
• Injection must be given to clean site using clean hands 
Choosing the injection site
Rate of insulin absorption depends on multiple factors including insulin related factors (physicochemical properties, excipients, injected volume, concentration, and dosage) and the clinical conditions during injection [orthostatic position, injection site, depth of injection, exercises, local massage, heat exposure, smoking, subcutaneous tissue thickness (SCT) and subcutaneous adipose tissue blood flow] [27] [28] [29] .
Overall, gender (higher risk in males), BMI (higher risk for < 25 kg/m 2 ), and injection site (higher risk for thigh) as combined with needle length (higher risk for ≥ 8 mm) and insertion angle (90º), are considered to determine estimates of risk of intramuscular insulin injection [30] [31] [32] .
Abdomen and buttock are the site of injections associated with fastest and slowest rates of insulin absorption, respectively, while lateral side of the thigh, not proximal to the knee, and upper arm have moderate absorption rates [25, [33] [34] [35] .
Available guidelines on insulin injection practice consider abdomen as the commonest injection site followed by buttocks and thigh [5, 22, 23] or arm, [24] [25] [26] and recommend selection of thigh [5, 23, 24, 26] and buttocks [5, 23, 26] for NPH, abdomen for soluble human insulin, [23, 26] abdomen (morning) and thigh or buttock (evening) for premixed insulins [23] , while no specific site selection was considered for insulin analogues [23, 26] (Table 2) .
Consensus statement on injection site selection
The expert panel recommends that abdomen (the site with the most consistent absorption) as followed by thighs and buttocks as the appropriate injection sites for adults, whereas the arm is not considered a preferred site for self-injection due to risk of intramuscular administration. Abdomen is considered to be potentially better choice of injection site for soluble human insulin due to characteristic fastest absorption, while thigh and buttocks are considered more appropriate for NPH injection since absorption is slowest from these sites. For rapid or long acting basal insulin analogues and GLP 1agonists, using any of the injection sites is possible as absorption rates do not appear to be site-specific.
Consensus statement 2. Injection site selection
• Abdomen, thighs and buttocks are the recommended injection sites for adults, with abdomen offering most consistent absorption
• The arm is not a preferred site for self-injection due to risk of intramuscular administration
• The thigh and buttocks may be preferred injection sites when using the NPH, since absorption is slowest from these sites
• The abdomen may be the preferred site for soluble human insulin since absorption is fastest there [5] • Clean site properly
• Alcohol if used, let it evaporate, as dry surface minimizes pain
• Do not use soap-based detergent, chloroxylenol, and cetrimide/chlorhexidine
• Inject if site is considered "socially clean"
• Rapid-acting and long acting basal insulin analogues may be given at any of the injection sites, as absorption rates do not appear to be site-specific 
Site rotation
Correct site rotation, defined as always injecting at least 1 cm from a previous injection, has been consistently shown to be the best way to safeguard normal tissue [4, 34, 36, 37] .
Worldwide Injection Technique Questionnaire (ITQ) 2014-2015 data reported that patients who rotate correctly tend to have lesser rates for hyperglycaemia, LH, unexplained hypoglycaemia and glucose variability [10, 38] . Incorrect rotation of sites was reported to be associated with 0.57% higher HbA 1c levels, 4.7 IU higher total daily insulin dose and higher frequencies of unexpected hypoglycaemia and glucose variability [10, 38] .
In a recent study comparing findings from Indian arm vs. rest of the world (ROW) in the ITQ 2014-2015 global study, correct site rotation was reported to be applied by similar percentage of patients in the India setting (68.1%) and rest of the world (ROW) (71.0%), whereas much higher percentage of patients in India than in ROW (48.7 vs. 18.4%) identified that they were never trained on correct site rotation [36] .
Notably, despite its association with lower HBA 1c levels, less LH, and more correct injection site rotation; routine inspection of injection sites by the HCP at least once a year was not met by nearly 80% of patients in India as well as in ROW [36, 38] .
Implementation of an easy-to-follow rotation scheme from the onset of injection therapy is considered important in acquisition of an appropriate site rotation practice. One scheme with proven effectiveness involves dividing the injection site into quadrants (or halves when using the thighs or buttocks), using one quadrant per week and moving always clockwise. Injections within any quadrant or half should be spaced at least 1 cm from each other in order to avoid repeat tissue trauma. Pump cannula should be placed at least 3 cm away from previous sites. HCPs should verify that the rotation scheme is being followed at each visit and give help and advice where needed (Figure 2, 3) • Abdomen -commonest site followed by buttocks, thigh and arm Available guidelines on site rotation recommend teaching a structured and easy-to-follow rotation scheme to patients, and emphasize rotating within one area rather than rotating to a different area and with dividing the injection site into quadrants (abdomen) or halves (buttock or thigh), using 1 quadrant/week and moving clockwise and spacing injections at least 1 cm from each other. Patient education and inspection at each visit is considered essential, while use of site rotation grids is considered useful in patients forgetting injection sites (Table 3 ) [5, [22] [23] [24] [25] [26] 42] .
Consensus statement on site rotation
The expert panel recommends teaching an easyto-follow rotation scheme to patients from the onset of injection therapy, use of a structured rotation plan including one quadrant per week and moving always in the same direction with spacing subsequent injections within the quadrant at 1 cm to avoid repeated trauma and review and emphasize the importance of discussing site rotation with patient at each visit. 
Choice of device and storage of insulins
Selection of the device
Factors underlying the choice of right device include biomechanical factors (accuracy, length of needle, degree of dose increment and suitability for children/visually/dexterity-challenged people), psychosocial factors (attractiveness, discreteness/ • Rotation within an area -critical for optimal absorption
• Rotation -within the same area, rather than from major site to site • Divide into quadrants (abdomen) or halves (buttock or thigh), use 1 quadrant/ /week and move clockwise
• New injection site should be at least 1-2 cm apart from the previous site
• HCPs -review site rotation scheme at least once a year /size, comfort/ease of use and ease of transport/storage), environmental factors (temperature stability, biodegradability/"green devices", availability of compatible insulins and availability of ancillary supplies), pragmatic factors (cost of device/insulin refills/needles, expected duration of insulin therapy with prescribed regimen and monthly dose requirement vis a vis capacity of device) and medication-counselling factors (time taken to reach, time taken to learn, risk of error in delivery and availability of post-prescription follow-up). The modern pen devices have various advantages over the conventional insulin delivery methods such as user-friendliness, comfort of injection, higher accuracy specially at low doses, the flexibility of incorporating insulin injections into a busy lifestyle which may improve diabetes control with much less effort, while maintaining the quality of life for the diabetic patients [43, 44] . Pen devices available in the market are summarized in Table 4 .
In a past study on the accuracy and precision of lowdose insulin administration via various devices including NovoPen ® (3.0 mL), BD-Mini Pen ® (1.5 mL), Humalog Pen ® (100 U/mL), 30G Precision Sure-Dose ® Insulin Syringes, 30G BD Ultra-Fine II ® Short Needle Syringes, and H-TRON-plus V100 ® insulin pump; the pen and pump devices were reported to be more accurate, and the pump to be more precise, than the syringes at the 1U and 2U doses. Syringes were considered to be dangerously inaccurate clinically, at the 1U dose ( Figure 4 ) [44] .
In a past study addressing dose accuracy of NovoPen ® 4 with respect to ISO tolerance limits [0.0-2.0 for a target dose of 1 U, 28.5-31.5 for 30 IU and 57.0-63.0 for 60 U, SD: ± 2.67 for each), NovoPen ® 4 was reported to be accurate before and after simulated lifetime use of 5475 injections in 5 years with mean dose of test medium delivered remained within the ISO tolerance limits at all doses tested and under conditions of mechanical and temperature stress ( Figure 5 ) [45] .
Comparison of minimum, medium, and maximum doses of FlexTouch ® (1/40/80 U), KwikPen ® (1/30/60 U) and SoloSTAR ® (1/40/80 U) in terms of dose accuracy in a past study revealed that FlexTouch ® delivered all doses consistently, as demonstrated by low standard deviations [46] . FlexTouch ® showed similar accuracy to KwikPen ® at 1 U and to SoloSTAR ® at 40 and 80 U and provided equivalent accuracy at medium and maximum doses with all tested pens, whereas it was significantly more accurate at delivering 1 U of insulin than SoloSTAR ® ( Figure 6 ) [46] . Available guidelines consider insulin pens as the injection devices of choice due to shorter needle size, psychological advantages, convenience, accuracy and adherence as well as cost benefits due to treatment adherence (Table 5) [22] [23] [24] 26] .
Consensus statement on choice of device
The expert panel recommends use of insulin pens over syringes for the convenience, ease of use, reduced fear of injections, greater treatment adherence and greater social acceptance. There are pen injectors dedicated to insulin preparations manufactured by different companies which may be used because they are compatible with insulin cartridges. However, Novo Pen ® 4 and Flex Touch ® are recommended over other devices for the ease of use, accuracy and lower dose force vs. other pen devices. 
Storage of insulins
For optimal effect, insulin need to be stored under refrigerated conditions, between 2 and 8°C as maintained below the freezer or in the butter compartment of most fridges, and be protected from light when vials or pens are unopened [47] . However, in India, up to 80% patients lack a good storage facility at home, while even in places where refrigerators are available, electrical supply may be erratic [47, 48] . The insulin pen in use (insulin cartridge inside) can be stored at room temperature (15-25°C) for 30 days [49] . However, the room temperature in many parts of India exceeds 25°C especially during summer season.
A survey in India showed approximately 75% of insulin to be stored at cool places, while cool places were not defined [8] . Additionally, the median time gap between taking out insulin vials from refrigerator and insulin injection was reported to be only 5 min, which is considered likely to cause pain at the injection sites [8] .
In another study performed in Puducherry, India, it was reported that storage of regular and biphasic insulin at 32°C and 37°C decreased the potency of insulin by 14 to 18% [50] , emphasizing a need for patient education about the temperature and duration of storage of insulin vials to maintain adequate glycaemic control [47] . Nonetheless, improvised practical methods of insulin storage being implemented in rural India with limited facilities are as follows (Figure 7) [47]. Convenience, accuracy and adherence Figure 7 . Improvised practical methods of storage in India -rural
• Storing insulin in a small bowl of water protected from exposure to direct sunlight and wetting of the label using a water-proof tape.
• Using a small clay pot or earthenware pitcher to reduce an exposure to external temperature variations with insulin vial cap is not submerged, and the labels with insulin name, date of opening, and date of expiry are preserved.
• Using thermo cool boxes, with ice packs inside them (replaced by frozen ones on weekly basis), as effective refrigeration devices for insulin that would keep the temperature within acceptable limits for many days.
• Using a good insulated extra vaccination boxes that can keep insulin stable for many days.
• Keeping a cool wet cloth around insulin to preserve insulin potency.
In fact, resource-poor mountainous areas such as Himalayas also pose significant challenges to insulin supply, storage and disposal where keeping insulin warm enough is an issue with temperature extremes range from 30°C in summer to -20°C in winter as well as high indoor temperature during winter since members of the family stay together in a single room warmed by an iron-framed oven [51] . Hence persons living with diabetes on insulin therapy report insulin storage to be a major challenge during winter, since they are unable to store their insulin vial and pens in living rooms, because of extreme heat, and cannot use adjoining rooms, as night-time temperatures routinely fall below freezing point [51] . Accordingly, patients are advised by HCPs to store insulin vials and pens by wrapping them in two to three layers of warm woollen cloths, made of sheep wool, in wooden or steel cupboards, as the local method of storing foodstuffs [51] .
Manufacturer instructions on storage of insulins are provided in Table 6 .
Consensus statement on storage of insulin
The expert panel recommends storage of injectable medicines in accordance with the manufacturer's instructions. Insulin should be discarded if it is past the expiry date, is open for more than a month, is discoloured or become cloudy. Insulin should be stored at refrigeration temperature (2-8ºC) until use, and at room temperature once in use, while it should never be frozen or exposed to extreme heat (> 30ºC) for prolonged periods. 
Safety precautions, disposal and complications
Safety precautions and sharp disposal practice
Insulin pens are only approved for single-patient use and even though the needles were changed between uses, the patients were at risk due to possible biological contamination in the pen cartridges [52, 53] . In accordance with widespread concern about disease transmission due to repeated instances of misuse of insulin pens, FDA, Institute for Safe Medication Practices (ISMP), and Centres for Disease Control (CDC) issues similar warnings against using the same insulin pen to administer insulin to multiple patients [53] [54] [55] .
Improper sharp disposal practices among diabetes patients have been considered to be as high as 80-90% [56, 57] .
ITQ 2014-2015 Study revealed a very large number of used diabetes sharps to still end up in the general community trash with use of a container specially made for used sharps by only 20.7% of patients and lack of a past training on proper disposal of sharps in 30% of patients [10] . Indian arm of ITQ 2014-2015 study revealed that almost 65% of patients were never trained on proper disposal of sharps [36] .
Nearly 3 billion injections (83% for curative purposes, 63% in an unsafe manner) is estimated to be administered annually in India [58] , whereas the proper way of disposing sharps is one of the important, but often neglected component of proper injection techniques [58] [59] [60] .
Accordingly, in a KAP study on disposal of sharp waste in India, 84.1% of diabetic patients were reported to discard the sharps directly into their household waste bins [61] . Authors also reported that 71% patients disposed at least 7 needles/week, 89% patients disposed at least 7 lancets/week, whereas only 14.1% diabetes patients received education from their HCP regarding proper sharp disposal [61] .
This seems notable given the higher likelihood of improper sharp disposal practice with lack of counselling from HCPs [60] , along with a wide gap between translation of research findings and their implementation in practice and poor adherence to established guidelines for sharp disposal practice in India [60, 62] .
India is home to a huge diabetic population and concerns over sharp disposal practices in diabetes self-management are therefore important and should not be neglected given the likelihood of outbreaks of blood-borne infections and related adverse health and economic outcomes [60] .
Current guidelines on safety precautions and disposal consider training of HCPs, caregivers and patients based on local regulations to be essential. The main recommendations include avoiding recapping, bending, or breaking a needle as well as disposing in household or public disposal system and using needle clipping device and puncture-resistant container (Table 7) [5, 22, 23, 25, 26].
Consensus statement on safety precautions and sharp disposal practice
The expert panel recommends single person use of syringes and pen needles, patient's education about the safe disposal of their used sharps with reinforcement during subsequent visits, following local regulations regarding sharps disposal, avoiding disposal of sharps material into the public rubbish or household garbage. 
Complications of insulin injections
ITQ 2014-2015 Study revealed higher rates of unexplained hypoglycaemia and glucose variability in those with LH, injecting into LH, incorrect rotation of sites and needle reuse [10] .
According to ITQ 2014-2015 data, LH was highly prevalent (30.8%), while associated with consumption of 10.1 IU more insulin daily, 0.55% higher HbA 1c levels, higher rates of unexplained hypoglycaemia and glycaemic variability as well as with incorrect rotation of injection sites, use of smaller injection zones and reuse of pen needles [38] .
Indian ITQ revealed 21.9% of Indian patients had nurse-confirmed LH with almost equivalent risk across sites (8.7-10.1%) except buttocks (0.0%) [36] . Injecting into LH was consistently reported to be associated with delayed or erratic insulin absorption, potentially worsening the diabetes management [63, 64] . In this regard, it should be noted that Indian patients with LH were found not to inject into LH lesions as frequently as in ROW (35.0% vs. 56.0%), while 53% were unaware of the reasons underlying this practice with convenience and pain less frequently cited by Indian patients compared to ROW (17.0 vs. 38.0%) [36] .
Although none is evidence-based, several approaches have been recommended in treatment of LH such as changing the insulin formulation (e.g., aspart to lispro, or lispro to glulisine, etc.), changing injection sites, or shifting to CSII and possibly cortisone injection [36] .
ITQ 2014-2015 data revealed that 60.2% of patients experience bleeding and bruising (never: 50.8%, sometimes: 41.5%, often: 7.3%) [38] . In Indian ITQ, 41.4% of Indian patients reported bleeding or bruising from their injection sites (never: 37.7%, sometimes: 53.6%, often: 7.8%) [36] .
Injection using a 4 mm needle at 90° is considered to deliver insulin into subcutaneous tissue for > 99.5% of times with minimal risk of intradermal (ID) injections. Majority of injections at four commonly-used sites with • Adequate training on safety and disposal -patients and caregivers
• Sharps containers in every ICU, ward and nursing station
• Used needles or syringes -puncture proof box/safety box/strong cardboard/ /glass container
• Label the box as biohazard and handover to health-care facility
• NACO guidelines -gives safe disposal methods a 4-5 mm needle at 90° would be delivered into the subcutaneous tissue with < 2% risk of intramuscular (IM) injections [30, 32] . When inserted 90° without pinch-up, the most commonly used needle worldwide (8 mm) has estimated IM risks of 25% and 9.7%, respectively, in the thigh and abdomen, versus 1.6% and 0.1%, respectively, with a 4 mm needle. A 45° insertion reduces, but does not eliminate, IM risk with longer needles [32] .
Risk of IM injection in considered to be higher in arm and thigh injections and further increase with increasing needle size, from 1% (4 mm) to 55% (12.7 mm, 27% for 45°) in the arm and from 1.6% (4 mm) to 63% (12.7 mm, 34% for 45°) in the thigh (Table 8 ) [32] .
ITQ 2014-2015 data revealed that pain was associated with larger needle size and needle reuse and increase as a function of the number of times the needle is reused [38] . Pain was commonly associated with bleeding, injecting through clothes, injecting insulin while it is still cold, LH, injecting into LH, incorrect site rotation, higher HbA 1c levels, lower BMI, younger age, and higher total daily dose of insulin [38] .
Indian ITQ revealed that 50% of Indian injectors had pain on injection [36] , while authors also emphasized that patient awareness of injection discomfort depends on several factors such as needle length, needle diameter, injection context and apprehension of HCPs [36, 65, 66] .
Past studies addressing injection pain reported no impact of injection speed (150, 300, and 450 µl/s; equivalent to 15-45 IU/s of U100 insulin) on pain [67] , whereas more pain with higher injection volume (≥ 1200 µl or 120 IU of U100 insulin) [67] [68] [69] and selection of thigh compared to abdomen as an injection site [67] . Nonetheless, it was concluded that injection pain is mild enough to be acceptable to most of patients particularly with today's very thin, short needles [36, 67] .
Current guidelines recommend regular inspection and palpation of sites, rotation of sites and avoiding needle reuse and injecting in LH to prevent LH; recommend reassurance for avoid occasional bleeding and bruising and review of technique for frequent bleeding and bruising, use shorter needles and avoid IM injection to prevent bleeding and bruising, recommend avoiding injection through clothes to prevent intradermal injection, avoiding 12.7 mm needles and injecting at 45 degree and using lifted skin fold or injecting abdomen in slim patients to prevent IM injection; and recommend injecting at room temperature, using distraction methods, using needles of shorter length and smaller diameter and a new needle at each injection, allowing topical alcohol (if used) to evaporate before injection, inserting needle in a quick smooth movement and injecting slowly and removing at same angle with not changing the direction of needle during insertion and withdrawal to prevent pain (Table 9 ) [5, [22] [23] [24] [25] [26] .
Consensus statement on complications of insulin injections
For LH, the expert panel recommends patient education about examining injection sites to detect LH and avoiding injection into the hypertrophic and atrophic areas. HCP inspection and palpation of injection sites at each visit, use of site rotation and non-reuse of needles are also recommended to prevent LH which should be ruled out as a cause of poor glycaemic control, hypoglycaemia and high glycaemic variability. For bleeding and bruising the expert panel recommends reassuring patients about no significant impact of occasional bruising or bleeding at site on insulin action, whereas a review of injection technique for frequent Table 9 . Guideline recommendations about complications of insulin injections • Penetrate skin quickly, don't move needle after insertion bruising or bleeding, and use of shorter needles for less frequent bleeding and bruising and consideration of the likelihood of IM injection for frequent bleeding and bruising with glycaemic variability. The expert panel recommends injecting into the abdomen or buttocks and use of shorter needle lengths, lifted skin fold and insertion of the needle at 45° to prevent IM injection and avoiding injection through clothing to prevent intradermal injection. For pain, the expert panel recommends considering all factors contributing to the perception of pain such as individual perception, needle length and diameter, injection technique and IM injection and recommends use of short and narrow-gauge (4-5-mm × 32G) insulin pen needles, injecting at room temperature and allowing topical alcohol (if used) to evaporate before injection, relaxing muscles at the site when injecting, using distraction methods, not reusing needles and penetrating skin quickly without changing needle direction during insertion or withdrawal to prevent pain.
Consensus statement 7. Complications of insulin injections
Lipohypertrophy
• Individuals should be taught to examine their own injection sites and how to detect lipohypertrophy 
Conclusion
This expert panel based consensus statement provides a simple and easily implementable practical educational guideline for HCPs and patients to optimize insulin injection practices (preparation and selection of injection sites, site rotation, selection of device, storage of insulins, safety precautions, sharp disposal practice and complications) in accordance with recent advances in device manufacturing, newer research findings, and updated international guidelines as well as widespread concerns about neglected safety precautions such as single-patient use of pens and appropriate sharp disposal practices. This seems important given the overall findings from ITQ studies that highlight the need of easy to use practical guidance to optimize insulin injection practices as well as findings specific to Indian cohort such as suboptimal rates for patient training on injection practice and routine check of injection sites by HCPs at every visit. Accordingly, the expert panel recommendations regarding insulin injection practices provided in this consensus statement emphasize: -injecting into a clean site after inspection and palpation and with use of soap and water for cleaning rather than disinfecting the skin; -selection of abdomen (offering the most consistent/fastest absorption) as followed by thighs and buttocks as the appropriate injection sites for adults, whereas potential of thigh and buttocks to be more appropriate for NPH due to slowest absorption from these sites along with no sitespecific alterations in absorption rate of basal insulin analogues; -teaching an easy-to-follow and structured site rotation scheme to patients from the onset of injection therapy and checking injection sites routinely at each visit; -preferring use of insulin pens (particularly Novo Pen ® 4 and Flex Touch ® for dose accuracy) over syringes for the convenience, ease of use, reduced fear of injections, greater treatment adherence and greater social acceptance; -storing injectable medicines in accordance with the manufacturer's instructions, with storing insulin at refrigeration temperature (2-8ºC) until use, and at room temperature once in use by preventing exposure to extreme cold or heat; -adhering to single person use of syringes and pen needles and providing patient education on safe sharp disposal practices per local regulations with avoiding disposal of sharps material into the public rubbish or household garbage and reinforcement during subsequent visits; -inspection and palpation of injection sites by HCPs at each visit to identify LH which should be ruled out as a cause of poor glycaemic control, hypoglycaemia and high glycaemic variability, and use of site rotation, non-reuse of needles, providing patient education about examining injection sites to detect LH and to avoid injecting into the hypertrophic and atrophic areas to prevent LH; reassuring patients about no significant effect of occasional bruising or bleeding at site on insulin action, whereas a review of injection technique, encouraging use of shorter needles and considering the likelihood of intramuscular injection and consequent glycaemic variability for frequent bruising or bleeding; injecting into the abdomen or buttocks and use of shorter needle lengths, lifted skin fold and insertion of the needle at 45º to prevent intramuscular injection and avoiding injection through clothing to prevent intradermal injection; considering all factors contributing to the perception of pain such as individual sensitivity, needle length and diameter, injection technique and intramuscular injection, use of short and narrow-gauge (4-5-mm × 32G) insulin pen needles, injecting at room temperature and allowing topical alcohol (if used) to evaporate before injection, using distraction methods, not reusing needles and penetrating skin quickly without changing needle direction during insertion or withdrawal to prevent pain.
Declaration of interest
